Disclosing individual CDKN2A research results to melanoma survivors: Interest, impact, and demands on researchers

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 3, 2011, Pages 522-529

  Christensen, Kurt D ^a   Roberts, J Scott ^a   Shalowitz, David I ^b   Everett, Jessica N ^c   Kim, Scott Y H ^c   Raskin, Leon ^c   Gruber, Stephen B ^a,c  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGED; ARTICLE; CANCER GENETICS; CANCER RESEARCH; CANCER SURVIVOR; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HETEROZYGOTE; HUMAN; INTERPERSONAL COMMUNICATION; MALE; MELANOMA; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; RESEARCH ETHICS; RESEARCH SUBJECT;

ADULT; AGED; DISCLOSURE; FEMALE; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MALE; MELANOMA; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; RISK FACTORS; SURVIVORS;

EID: 79955782525     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-1045     Document Type: Article

References (31)

1. Shalowitz DI, Miller FG. Communicating the results of clinical research to participants: attitudes, practices, and future directions. PLoS Med 2008;5:e91.
2. Keogh LA, Southey MC, Maskiell J, Young MA, Gaff CL, Kirk J, et al. Uptake of offer to receive genetic information about BRCA1 and BRCA2 mutations in an Australian population-based study. Cancer Epidemiol Biomarkers Prev 2004;13:2258-63. (Pubitemid 40054326)
3. Partridge AH, Winer EP. Sharing study results with trial participants: time for action. J Clin Oncol 2009;27:838-9.
4. Udayakumar D, Tsao H. Melanoma genetics: an update on risk-associated genes. Hematol Oncol Clin North Am 2009;23:415-29.
5. Kefford R, Bishop JAN, Tucker M, Bressac-de Paillerets B, Bianchi-Scarra G, Bergman W, et al. Genetic testing for melanoma. Lancet Oncol 2002;3:653-4. (Pubitemid 35314906)
6. Kasparian NA, Meiser B, Butow PN, Soames Job RF, Mann GJ. Anticipated uptake of genetic testing for familial melanoma in an Australian sample: an exploratory study. Psychooncology 2007;16:69-78. (Pubitemid 46189079)
7. de Snoo FA, Riedijk SR, van Mil AM, Bergman W, ter Huurne JA, Timman R, et al. Genetic testing in familial melanoma: uptake and implications. Psychooncology 2008;17:790-6.
8. Kasparian NA, Meiser B, Butow PN, Simpson JM, Mann GJ. Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families. Genet Med 2009;11:265-78.
9. Aspinwall LG, Leaf SL, Dola ER, Kohlmann W, Leachman SA. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families. Cancer Epidemiol Biomarkers Prev 2008;17:1510-9.
10. Begg CB, Hummer AJ, Mujumdar U, Armstrong BK, Kricker A, Marrett LD, et al. A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma. Int J Epidemiol 2006;35:756-64. (Pubitemid 43985574)
11. Berwick M, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, et al. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev 2006;15:1520-5. (Pubitemid 44299326)
12. Heshka JT, Palleschi C, Howley H, Wilson B, Wells PS. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med 2008;10:19-32.
13. Douma KFL, Aaronson NK, Vasen HFA, Bleiker EMA. Psychosocial issues in genetic testing for familial adenomatous polyposis: a review of the literature. Psychooncology 2008;17:737-45.
14. Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, et al. A randomized trial of APOE genotype disclosure for risk of Alzheimer's disease: the REVEAL Study. N Engl J Med 2009;361:245-54.
15. Rew L, Kaur M, McMillan A, Mackert M, Bonevac D. Systematic review of psychosocial benefits and harms of genetic testing. Issues Ment Health Nurs 2010;31:631-45.
16. Roberts JS, Shalowitz DI, Christensen KD, Everett JN, Kim SY, Raskin L, et al. Returning individual research results: development of a cancer genetics education and risk communication protocol. J Empir Res Hum Res Ethics 2010;5:17-30.
17. Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 1996;275:1885-92.
18. Griffin CA, Axilbund JE, Codori AM, Deise G, May B, Pendergrass C, et al. Patient preferences regarding recontact by cancer genetics clinicians. Fam Cancer 2007;6:265-73. (Pubitemid 47175002)
19. Rumpf H-J, Meyer C, Hapke U, John U. Screening for mental health: validity of the MHI-5 using DSM-IV Axis I psychiatric disorders as gold standard. Psychiatry Res, 2001;105:243-53. (Pubitemid 34117650)
20. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med 1979;41:209-18. (Pubitemid 9219271)
21. Mujumdar UJ, Hay JL, Monroe-Hinds YC, Hummer AJ, Begg CB, Wilcox HB, et al. Sun protection and skin self-examination in melanoma survivors. Psychooncology, 2009;18:1106-15.
22. Smith M, Freivogel M, Parrott S. Professional Status Survey 2008. Chicago, IL: National Society of Genetic Counselors, Inc.; 2009.
23. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8. (Pubitemid 26337709)
24. Beran TM, Stanton AL, Kwan L, Seldon J, Bower JE, Vodermaier A, et al. The trajectory of psychological impact in BRCA1/2 genetic testing: does time heal? Ann Behav Med 2008;36:107-16.
25. Bookman EB, Langehorne AA, Eckfeldt JH, Glass KC, Jarvik GP, Klag M, et al. Reporting genetic results in research studies: summary and recommendations of an NHLBI working group. Am J Med Genet A 2006;140:1033-40.
26. Kefford RF, Bishop JAN, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999;17:3245-51. (Pubitemid 29470659)
27. Rosenstock IM. Historical origins of the Health Belief Model. Health Educ Monogr 1974;2:328-35.
28. Fernandez CV, Kodish E, Shurin S, Weijer C. Offering to return results to research participants: attitudes and needs of principal investigators in the Children's Oncology Group. J Pediatr Hematol Oncol 2003;25:704-8. (Pubitemid 37087506)
29. Shalowitz DI, Miller FG. Disclosing individual results of clinical research: implications of respect for participants. JAMA 2005;294:737-40. (Pubitemid 41159294)
30. McGuire AL, Beskow LM. Informed consent in genomics and genetic research. Annu Rev Genomics Hum Genet 2010;11:361-81.
31. Cooper DN, Chen J-M, V. Ball E, Howells K, Mort M, Phillips AD, et al. Genes, mutations, and human inherited disease at the dawn of the age of personalized genomics. Hum Mutat 2010;31:631-55.